Type 2 Biomarkers Define a Prevalent Phenotype in Moderate-to-Severe, Uncontrolled Asthma Patients: A Pooled Analysis from Lebrikizumab All-Comers Phase 2 Trials

Type 2 Biomarkers Define a Prevalent Phenotype in Moderate-to-Severe, Uncontrolled Asthma Patients: A Pooled Analysis from Lebrikizumab All-Comers Phase 2 Trials

Conclusions In a pooled analysis of three trials designed to evaluate the effects of lebrikizumab treatment in moderate-to-severe uncontrolled asthma, 68% of patients had evidence of Type 2 inflammation using the specified cut-off values for periostin, blood eosinophils and FeNO.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB108-AB108
Hauptverfasser: Korenblat, Phillip E., MD, FAAAAI, Hanania, Nicola A., MD, Corren, Jonathan, MD, Olssen, Julie K., MD, MS, Kamath, Nikhil, MD, Gray, Sarah, PhD, Martin, Nicolas, Holweg, Cecile T.J., PhD, Matthews, John G., MB, BS, MRSCP, PhD, Limb, Susan L., MD, Korom, Stephan
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Asthma
Biomarkers
Genotype & phenotype
Health care industry
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Conclusions In a pooled analysis of three trials designed to evaluate the effects of lebrikizumab treatment in moderate-to-severe uncontrolled asthma, 68% of patients had evidence of Type 2 inflammation using the specified cut-off values for periostin, blood eosinophils and FeNO.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.478